Project Grant R01CA294640
Award Date
8/1/25
Completion Date
7/31/30
Dollars Obligated
$714K
Federal Agency
National Cancer Institute
Awardee
Cleveland Clinic Lerner College Of Medicine Of Case Western Reserve University (M5QFLTCTSQN6)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Cleveland, OH 44195, USA
Similar Awards
This Project Grant award of $487,393.00 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program supports research on backup DNA repair mechanisms in homologous recombination deficient (HRD) cancers. The research aims to determine the role of key proteins like RAD52, HELQ, and POLQ in backup double-strand break repair pathways when the primary homologous recombination pathway is inactivated in certain cancer types. The goal is to identify...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides funding to support the computational research and platform development activities of a laboratory-based research specialist at the Cleveland Clinic Lerner College of Medicine. The key products and services delivered under this $212,567 award, spanning from September 2024 to August 2029, include: Computational analysis of cancer patient-derived next-generation...
This Project Grant award of $577,818 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop new effective therapeutic combinations to boost the "abscopal effect" and improve clinical outcomes for patients with advanced cancers treated with radiotherapy. The funded research project will: 1) Dissect the mechanisms by which the immune checkpoint molecule B7-H3 impairs CD8 T cell cytotoxicity, using proximity labeling technologies and mouse models, and...
This Project Grant award of $400,890.00 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to profile patient-specific tumor-microbiome interactions and conduct quantitative molecular analyses to elucidate microbiome-mediated modulation of immune checkpoint molecules in mismatch repair-proficient, microsatellite-stable colorectal tumors. The award, granted to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, will utilize...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) provides $581,381 to the Sloan-Kettering Institute for Cancer Research to investigate the role of microhomology-mediated end-joining (MMEJ) in mitosis and its impact on drug resistance. The research aims to better understand DNA damage repair pathways and how they contribute to genomic instability and cancer development, with the goal of informing more...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is providing $827,942.00 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to investigate a novel inhibitory receptor that regulates the persistence and function of chimeric antigen receptor (CAR)-engineered T cell therapy for lymphoma. The key objectives are to: 1) examine the causal role of this inhibitory receptor axis in impairing the therapeutic...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $238,722 to the Sloan-Kettering Institute for Cancer Research to investigate the role of mutagenic DNA repair in the persistence of cancer cells. The key objectives are to: Investigate persistence in response to PARP inhibitor treatment of BRCA1/2 cancer cells Examine mechanisms of mutagenic DNA repair in persister colorectal cancer cells Use high-content microscopy to...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $689,934 to the Dana-Farber Cancer Institute (DFCI) to conduct research on the genetic factors underlying immune-related adverse events (IRAEs) associated with immune checkpoint inhibitor (ICI) cancer treatments. The key objectives are to: 1) Perform the largest genome-wide association study (GWAS) of IRAEs across over 13,000 ICI-treated patients, to identify shared and...
The National Cancer Institute awarded a $340,072 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. The grant supports research to evaluate TMU27A, a novel non-nucleoside ribonucleotide reductase (RNR) inhibitor, as a potential treatment for metastatic breast cancer. Proposed studies will investigate TMU27A's impact on genome stability, efficacy, and safety compared to the current RNR...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $127,629 to the President and Fellows of Harvard College's Harvard T.H. Chan School of Public Health to conduct research on the role of human leukocyte antigen (HLA) variations in cellular immunity and the efficacy of immune checkpoint inhibitor monotherapy for non-small cell lung cancer patients. The key objectives are to: 1) identify the mechanisms linking germline and somatic HLA...